| JAZZ:Jazz Pharmaceuticals PLC | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
1.14% $1.55
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| FDA Approves Zepzelca(R) (lurbinectedin) and Atezolizumab (Tecentriq(R)) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer |
|
| PR Newswire |
|
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab combination added to National Comprehensive Cancer Network(R) Guidelines for SCLC |
| Full Story → |
|
| Headline News |
|
| Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav(R) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses |
| 7:45a ET September 22 '25 PR Newswire |
|
|
| Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network(R) (NCCN(R)) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma |
| 7:45a ET September 9 '25 PR Newswire |
|
|
| Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference |
| 4:15p ET August 21 '25 PR Newswire Europe |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| October 16 '25. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, October 15 '25. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
6.09%
